MannKind garners $175M to push inhaled diabetes therapy

The chairman and CEO of MannKind joined with institutional investors in a $175 million private placement. The money will be used to advance MannKind's Technosphere Insulin System, which is currently in phase III clinical trials in the US and Europe as a treatment for diabetes. Company namesake Alfred Mann is putting up half of the money. Valencia, California-based MannKind has been heavily criticized recently as it tries to catch up with competitors already far ahead in the race for an inhaled insulin product.

- read this press release for more

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.